Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Wasp venom offers hope for cancer patients
brazilian wasp
The wasp, native to Brazil, produces a venom containing a cancer-fighting ingredient.

Study shows how toxin selectively attacks cancer cells
 
Scientists say the venom of a Brazilian wasp may one day be used in the fight against cancer.

New research reveals for the first time how a toxin contained in the venom is able to attack cancer cells, leaving normal cells unharmed.

To protect itself from predators, the social wasp Polybia paulista produces a venom containing the toxin MP1 (Polybia-MP1).

Laboratory testing has shown the toxin can inhibit the growth of bladder and prostate cancer cells, as well as the multi-drug resistant leukaemic cells.

Until now it was not understood how MP1 is able to do this without damaging normal cells. But according to new research published in the Biophysical Journal, the toxin selectively attacks lipids that are abnormally distributed across the surface of cancer cells. In a matter of seconds, this creates gaping holes, allowing molecules that are vital for cell function to escape.

Co-author Dr Paul Beales from the University of Leeds said this approach to treatment would be "an entirely new class of anti-cancer drugs" and could help develop new combination therapies, where multiple drugs are used at the same time to attack different parts of the cancer cells.

In future, the researchers plan to alter the amino acid sequence of MP1 to find out more about the peptide's structure, increasing its potential for clinical purposes.

"Understanding the mechanism of action of this peptide will help in translational studies to further assess the potential for this peptide to be used in medicine," Dr Beales explained.

"As it has been shown to be selective to cancer cells and non-toxic to normal cells in the lab, this peptide has the potential to be safe, but further work would be required to prove that."

Image © Prof. Mario Palma/Sao Paulo State University

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.